Cargando…
GnRHa/Stanozolol Combined Therapy Maintains Normal Bone Growth in Central Precocious Puberty
BACKGROUND: Gonadotropin-releasing hormone agonist (GnRHa) is the gold standard in the treatment of Central Precocious Puberty (CPP) with progressive puberty and accelerative growth. However, GnRHa treatment is reported to result in growth deceleration and prevents growth plate development which lea...
Autores principales: | Zhu, Shunye, Long, Lingli, Hu, Yue, Tuo, Ying, Li, Yubin, Yu, Zhenhua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221533/ https://www.ncbi.nlm.nih.gov/pubmed/34177807 http://dx.doi.org/10.3389/fendo.2021.678797 |
Ejemplares similares
-
Treatment of central precocious puberty using low dose GnRH analogs (GnRHa)
por: Jahagirdar, Rahul, et al.
Publicado: (2015) -
A single sample GnRHa stimulation test in the diagnosis of precocious puberty
por: Yazdani, Parvin, et al.
Publicado: (2012) -
Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty
por: Lewis, Katherine A, et al.
Publicado: (2009) -
The Efficacy of GnRHa Alone or in Combination with rhGH for the Treatment of Chinese Children with Central Precocious Puberty
por: Wang, Mengjie, et al.
Publicado: (2016) -
Response of South Indian girls with central precocious puberty to gonadotrophin analogue (GnRHa) therapy – a single center experience
por: Selvaraj, Meghana, et al.
Publicado: (2021)